logo
Scientists Find Jupiter Used to Be More Than Twice Its Current Size

Scientists Find Jupiter Used to Be More Than Twice Its Current Size

Yahoo25-05-2025
You don't need us to tell you that Jupiter, which has more than twice the mass of all the other planets in the Solar System combined, is the biggest game in town (other than the Sun, at least.)
But believe it or not, it may have once been even bigger. Try more than double its current size, according to new research from Caltech and the University of Michigan — boasting enough volume to fit 2,000 Earths inside it with room to spare. Over time, the bloated world cooled off, contracting to the relatively humbler size it is today.
The findings, published in a new study in the journal Nature Astronomy, provide a window into the Solar System's early evolution, around 3.8 million years after the first solids formed. Jupiter, with its enormous gravitational pull — and as the first planet to form — would have played an instrumental role in determining how the orbits of the nascent planets eventually settled.
"Our ultimate goal is to understand where we come from, and pinning down the early phases of planet formation is essential to solving the puzzle," co-lead author Konstantin Batygin, a professor of planetary science at Caltech, said in a statement about the work. "This brings us closer to understanding how not only Jupiter but the entire Solar System took shape."
The clues to uncovering this early episode of Jupiter's past lie in two of its small moons, Amalthea and Thebe, which exhibit unusual orbits that aren't fully explained by their host's current size.
To examine this discrepancy, the researchers bypassed existing planetary formation models and focused on aspects of the Jovian system that could be directly measured, including the orbital dynamics of the tiny moons and the planet's angular momentum.
Their calculations revealed that, around 4.5 billion years ago, Jupiter must have had a radius up to 2.5 times greater than it is today. Likewise, its magnetic field — terrifyingly, as it's already 20,000 stronger than the Earth's — would have been a staggering 50 times more powerful.
This dramatically shapes our idea of Jupiter in a critical moment in the Solar System's evolution, when the great disk of matter surrounding the Sun called the protoplanetary disk, which gave birth to the planets, evaporated.
Mind-boggling as they are, these findings, the researchers say, are consistent with the prevailing core-accretion theory describing how giant planets formed. According to this theory, the giant planets began as heavy, solid cores floating on the farther and colder side of the protoplanetary disk, pulling in the lighter gas molecules surrounding them — first gradually, and then after passing a threshold of mass, much more rapidly.
The exact details surrounding the planets' origins are still hotly contested. But the researchers say they've made the most precise measurements to date of primordial Jupiter's size, spin rate, and magnetic conditions, which will be indispensable to furthering our understanding of the Solar System's architecture.
"What we've established here is a valuable benchmark," Batygin said. "A point from which we can more confidently reconstruct the evolution of our Solar System."
More on astronomy: Astronomers Baffled by a Suspicious, Perfectly Round Sphere in Our Galaxy
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dental Floss Could Deliver Next-Gen Vaccines, No Needles Required
Dental Floss Could Deliver Next-Gen Vaccines, No Needles Required

Gizmodo

time24 minutes ago

  • Gizmodo

Dental Floss Could Deliver Next-Gen Vaccines, No Needles Required

Flu shot season is around the corner, and while injections remain the most common form of vaccination, scientists are working hard to find other ways to deliver inoculations that don't involve shoving a needle into your flesh. And in a new study, researchers think they might have found another novel approach: dental floss. In the new work, a team of scientists based in the U.S. demonstrated how this might work on lab mice, finding that vaccine delivery via dental floss was more effective at stimulating antibody production than if the vaccine was delivered under the mice's tongues and about as effective as a nasal spray delivery method. If the results hold true for humans, then some vaccines could be given via tooth tape and without the need for needles. 'Here we show that flat tape dental floss can deliver vaccines through the junctional epithelium of the gingival sulcus, exploiting its naturally leaky properties,' the researchers wrote in the study, which was published in July in the journal Nature Biomedical Engineering. The junctional epithelium is the technical term for the deep tissue between the tooth and the gum. Epithelial tissues are one of three layers of so-called mucosal surfaces, which are the membranes that lubricate and protect your body's organs and cavities, including your nose, mouth, and intestines. Many pathogens like influenza and Covid-19 can enter the body through these mucosal surfaces. 'If a vaccine is given by injection, antibodies are primarily produced in the bloodstream throughout the body, and relatively few antibodies are produced on mucosal surfaces,' Harvinder Singh Gill, co-author of the study and a professor in Nanomedicine at North Carolina State University, explained in a statement. 'But we know that when a vaccine is given via the mucosal surface, antibodies are stimulated not only in the bloodstream, but also on mucosal surfaces.' 'This improves the body's ability to prevent infection, because there is an additional line of antibody defense before a pathogen enters the body,' he added. Because the tissue in between our teeth and gums is more permeable than other similar tissues, like those lining your stomach, lungs, and intestines, then it should be able to introduce a vaccine into the body relatively easily, triggering the production of antibodies throughout the mucosal layers. To test this idea, the researchers applied peptide flu vaccine on unwaxed dental floss, and then used it to floss the teeth of lab mice. Gill and colleagues then compared the animals' antibody production to that of mice that either received the peptide flu vaccine via a nasal spray or under their tongues. The dental floss vaccine delivered significantly superior antibody production on mucosal surfaces than the under-the-tongue inoculation, and was comparable to the nasal spray. 'This is extremely promising, because most vaccine formulations cannot be given via the nasal epithelium—the barrier features in that mucosal surface prevent efficient uptake of the vaccine,' said Gill, adding that nasal delivery also carries the risk of the vaccine reaching the brain, which could pose safety concerns. 'Vaccination via the junctional epithelium offers no such risk,' he said. The team also tested the floss approach with three other vaccine classes—proteins, inactivated viruses, and mRNA—and revealed that the novel method triggered antibodies both in the bloodstream and mucosal surfaces in all of them. What's more, their efficacy wasn't impeded if the mice consumed food or water right after flossing. To investigate the practicality of the flossing approach, the researchers also tested its mechanics with humans. Using floss picks, they coated the tape with food dye and asked study participants to try and get it as deep between their teeth and their gums as they could. Participants were able to deposit around 60% of the dye in the gum pocket, indicating that vaccine-coated floss picks could be an effective way to deliver vaccines to that tissue. As for costs, the researchers think that it would be similar in price to other vaccine delivery techniques. However, there are some inherent limitations to a floss vaccine. 'For example, it can only be used for individuals with teeth,' the researchers explained in the study. 'Therefore, this approach cannot be used in neonates [newborns] until they experience teeth eruption, which typically occurs at around 6 months of age. Further, the impact of gingival tissue infection on vaccination is unclear. Additional studies are required to answer this question.'

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Yahoo

timean hour ago

  • Yahoo

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the 'CaRe PC' trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment. INKmune™ was well tolerated at all three dose levels in the trial, demonstrating an excellent safety profile, the primary endpoint of CaRe PC. Additionally, patients with low NK cell activation saw the greatest improvement in their biomarkers of NK cell activation, defining the target population for the next trials. 'INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease,' stated Dr. Mark Lowdell, CSO at INmune Bio. 'Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing.' Following the successful completion of the Phase 1/2 trial of INKmune™ in patients with advanced-stage disease, INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease, enabling a more robust measurement of the drug's effects and potential clinical benefits. About INKmune™ INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer patient's resting NK cells into tumor killing memory-like NK cells (mlNK cells). INKmune™ treatment converts the patient's own NK cells into mlNK cells. In patients, INKmune™ primed tumor killing NK cells have persisted for more than 100 days. These cells function in the hypoxic TME because due to upregulated nutrient receptors and mitochondrial survival proteins. INKmune™ is a patient friendly drug treatment that does not require pre-medication, conditioning or additional cytokine therapy to be given to the patients. INKmune™ is easily transported, stored and delivered to the patient by a simple intravenous infusion as an out-patient. INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer. INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US this year. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio's product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss Co-founder and Chief Financial Officer (858) 964-3720 info@ Daniel Carlson Head of Investor Relations (415) 509-4590 dcarlson@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

Yahoo

time2 hours ago

  • Yahoo

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

BMI OrganBank is developing novel medical devices with potential to significantly reduce the waitlist for lifesaving organ transplants, beginning with kidneys FDA Breakthrough Device Designation secures expedited FDA engagement in advance of clinical studies planned for early next year WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated "We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week." About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store